Dalton Pharma News

Dalton Enters Into Agreement With the USAMMDA in Support of the US Army’s Drug Development Program

Dalton Pharma Services, a privately owned pharmaceutical services provider, today announced that it has entered into a contract service agreement with the United States Army Medical Materiel Development Activity (USAMMDA) in support of the US Army’s product development program for the treatment of severe or complicated malaria due to Plasmodium falciparum. Under the awarded contract with USAMMDA, Dalton will provide cGMP sterile powder filling, aseptic liquid filling, quality control release testing and ICH stability services for their anti-malarial drug development program.

Malaria remains one of the most important infectious disease threats to service members deployed to endemic areas and has a long history as the cause of disease and non-battle injury to military personnel. Despite the use of preventative measures to reduce the risk of malarial infection, service members continue to contract this disease due to operational constraints, lack of compliance, and drug-resistant malarial parasites.

“The leadership role taken by USAMMDA in the development of this important therapy for malaria treatment is to be commended, and we are privileged to support this critical program developing safe and effective anti-malarial drugs for emergency treatment protocols”, said Peter Pekos, President and CEO of Dalton.

USAMMDA is the Department of Defense's (DoD) advanced development activity for products designed to protect and preserve the lives of Warfighters. USAMMDA develops new drugs, vaccines and medical support equipment that enhances readiness, ensures the provision of the highest quality medical care to the DoD and maximizes survival of medical casualties on the battlefield.

About Dalton:
Dalton Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada approved and FDA registered cGMP contract service provider of integrated chemistry, drug development and manufacturing services to the pharmaceutical and biotechnology industries. We bring 30 years of experience to our client's projects and emphasize quality, speed and flexibility.

Dalton can accelerate your drug development program by integrating process development, cGMP API manufacturing and sterile or solid finished dose manufacturing all at a single location. For our full range of in-house services including cGMP sterile fill/finish services please visit https://www.dalton.com

Our CMO 2016 Leadership Awards in the categories of Quality, Reliability, Capabilities, Expertise and Compatibility including “On-Time Delivery” and “Right First Time” from Life Science Leader reflect our ongoing commitment to our clients, peers and the business community.

In 2016 Dalton was certified as A Great Place to Work.

Peter Pekos
President & CEO
Dalton Pharma Services
349 Wildcat Road
Toronto, Ontario
Tel: 416-661-2102